BRISBANE, California, August 14, 2026, 13:19 EDT — U.S. cash markets traded during regular hours.
- Vera Therapeutics stock gained 9.7% to close at $31.70, having earlier reached $37.24 during the session.
- Kynam Capital reported a 4.01% stake, a decrease from 5.37% the previous year.
- Vera’s cash reserves of $499.2 million are enough to fund approximately 14.5 months at the company’s operating burn rate from the first half.
Shares of Vera Therapeutics, Inc. NASDAQ:VERA rose 9.7% on Friday, with traders reassessing the revenue outlook for its recently introduced kidney treatment. The company topped Yahoo Finance’s U.S. gainers leaderboard in afternoon deals.
The action increased Vera’s equity value by approximately $202 million. The commercial challenge persists, however. Trutakna’s yearly list price stands at $425,000, and Vera’s operating cash burn for the first half, when annualized, is close to $414 million.
At 13:04 EDT, shares were at $31.70, higher by $2.81. Earlier in the session, they had climbed 28.9% at their peak before retreating to lose almost half of those gains.
| Friday trading measure | Value | Investor read-through |
|---|---|---|
| Last price | $31.70 | Up 9.7% |
| Intraday high | $37.24 | 28.9% above prior close |
| Intraday low | $29.60 | 2.5% above prior close |
| Volume | 3.84 million shares | Busy afternoon session |
| Market value | $2.28 billion | Roughly $1.78 billion excluding June cash |
A filing on Friday offered a contrasting perspective. Kynam Capital Management reported shared voting and dispositive authority over 2.89 million shares, representing 4.01% of the class. The filing indicated ownership at 5% or less.
| Kynam ownership | June 30, 2025 | June 30, 2026 | Change |
|---|---|---|---|
| Shares with shared control | 3,426,887 | 2,890,059 | -536,828 |
| Declared stake | 5.37% | 4.01% | -1.36 points |
| Shift in share count | — | — | -15.7% |
| Worth at $31.70 | — | $91.6 million | Preliminary |
The comparison relies on Kynam’s prior filing for the June 2025 stake. Dropping under the 5% threshold limits future updates on Schedule 13G. The information does not indicate if any further trades took place following Friday’s rally.
Vera has become a commercial-stage biotechnology company. In July, the FDA gave accelerated approval to Trutakna for adults who have primary IgA nephropathy with a risk of disease progression. Trutakna demonstrated a 42% reduction in urine protein compared to placebo after 36 weeks.
Chief Executive Marshall Fordyce stated that Vera is “focused on a successful U.S. launch of TRUTAKNA.” Management said early response has been positive. The company has yet to post any product revenue. Vera second-quarter results
| Commercial-finance measure | Reported value | Preliminary investor calculation |
|---|---|---|
| June cash and securities | $499.2 million | 14.5 months at H1 burn rate |
| Conditional debt capacity | Up to $425 million | 26.8 months when adding full capacity |
| H1 operating cash use | $206.8 million | $413.6 million if annualized |
| Q2 net loss | $109.5 million | Up 43.0% compared with previous year |
| Annual list price per patient | $425,000 | Approximately 973 treatment-years match the annualized burn |
The 973-patient number does not represent a break-even projection. It results from dividing annualized cash usage by the gross list price. Actual cash collected per patient will be reduced by rebates, discounts, expenses related to launch, and patient treatment persistence.
Based on Friday’s market capitalization, investors are effectively valuing the company at about 5,360 annual treatment courses at the list price. When accounting for June cash, this adjusts to around 4,190 courses. These are initial comparisons and do not represent revenue projections.
The next clinical milestone is approaching. Vera anticipates releasing final ORIGIN 3 kidney-function results in the third quarter. The company intends to submit a supplemental application in the fourth quarter, aiming for potential full approval in 2027.
Wall Street sentiment is upbeat, though targets vary significantly. Fourteen analysts have a consensus price target of $81.15, representing a 156% premium over Friday afternoon’s price.
| Analyst recommendation | Count | Share of 14 ratings |
|---|---|---|
| Strong buy | 1 | 7.1% |
| Buy | 11 | 78.6% |
| Hold | 1 | 7.1% |
| Sell | 1 | 7.1% |
| Average target | $81.15 | 156% above $31.70 |
| Target range | $34 to $125 | Up 7% to up 294% |
Risks: Accelerated approval requires supporting confirmatory data. Insufficient ORIGIN 3 results on kidney function may jeopardize full clearance. Delayed availability, insurer scrutiny, or increased dilution could further impact launch economics.
Friday’s rally brought back some optimism. The tougher challenge is quantifiable. Vera needs to convert its premium-priced medicine into sustained prescriptions before its cash reserves dwindle.
Related articles: Pharmaceuticals
